spacer
home > epc > autumn 2018 > accelerating development
PUBLICATIONS
European Pharmaceutical Contractor

Accelerating Development

Over the last 10 years, unprecedented advances in technology have revolutionised how people communicate, collaborate, and transact business, whether paying for groceries, video conferencing with colleagues from around the world, collaborating on editing and sharing documents, or analysing data – all from the palm of a hand. For context on how exponential these advances have been, a smartphone from 2014 is able to process information 100 million times faster than the supercomputers that NASA used to guide the Apollo missions to the moon.

Other industries – even those that are heavily regulated, like the financial sector – have integrated technology into their business models to automate processes and are using predictive modelling for better decision making. However, why not the pharmaceutical industry, especially now, when clinical trial performance benchmarks reveal an industry that is performing worse overall than a decade ago. So why is pharma slow in adopting new technologies to reverse these trends?

A Broken Model

Between 2005-2015 the number of countries involved in Phase 3 clinical trials has doubled, and the number of investigative sites has increased by 63%. Simultaneously, the mean number of patients declined by 18%, adding complexity to study startup processes (1). For example, site selection and initiation now takes an average of nearly eight months – longer than it did a decade ago – as more researchnaïve sites are being used. 28% of sites engaged represent new relationships with the sponsor or CRO, which adds 9.9 weeks to site initiation timelines compared to when the sponsor or CRO has a pre-existing relationship with the site (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Brion Regan has over 13 years of industry experience and has established himself as a thought leader in the application of data-driven process optimisation and cloud-based technologies to the clinical research space. As the Director of Product Management for ERT’s Trial Oversight Suite, he is leading the commercial development and management of the company’s growing portfolio of Software as a Service solutions. Prior to ERT, Regan served on the executive leadership team at technology start-up eClinical Insights as Head of Strategic Development. He has also previously held various positions in product marketing and business development at PharmaPros Corporation.
spacer
Brion Regan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Realising the potential of single-use technology – As published in Manufacturing Chemist

In this article Zenith Technologies’ Global Director of Managed Services David Staunton and Scott Ripley, Global Marketing Director at GE Healthcare, discuss the benefits and patient impact of single-use technology with Manufacturing Chemist.
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

 
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement